Ultragenyx Pharmaceutical RARE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's total liabilities?
- Ultragenyx Pharmaceutical (RARE) reported total liabilities of $1.53B in Q1 2026.
- How has Ultragenyx Pharmaceutical's total liabilities changed year-over-year?
- Ultragenyx Pharmaceutical's total liabilities increased by 31.4% year-over-year, from $1.16B to $1.53B.
- What is the long-term trend for Ultragenyx Pharmaceutical's total liabilities?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total liabilities has grown at a 21.5% compound annual growth rate (CAGR), from $605.18M to $1.61B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.